Discover
llllllllllOtezla (apremilast) / AmgenLong-term Study of Apremilast (CC-10004) in Pediatric Subjects from 6 Through 17 Years of Age with Moderate to Severe Plaque Psoriasis Estudio a largo plazo de apremilast (CC-10004) en pacientes pediátricos de 6 a 17 años con psoriasis en placas de moderada a grave (clinicaltrialsregister.eu) - Aug 18, 2020 - P3; N=140; Ongoing; Sponsor: Celgene Corporation`Amgen Inc.llllllllllIlumya (tildrakizumab-asmn) / Sun Pharma, AlmirallKangzhe Pharmaceutical (00867): Tiralizumab injection, a psoriasis drug, was approved for clinical trials [Google translation] (Eastmoney.com) - Aug 19, 2020 - "CMS...announced that the Chinese State Drug pull natalizumab injection for management of drug clinical Office on 18 August 2020 issued by approved test notification form agreeing to carry out the treatment of moderate to evaluate Tildrakizumab in Chinese population...on the efficacy and safety of patients with severe plaque psoriasis."llllllllllserlopitant (JTS 661) / Menlo TherapStudy of the Long Term Safety of Serlopitant for the Treatment of Pruritus (Itch) (clinicaltrials.gov) - Aug 18, 2020 - P3; N=558; Terminated; Sponsor: Menlo Therapeutics Inc.; Trial completion date: May 2021 --> Jun 2020; Active, not recruiting --> Terminated; Trial primary completion date: May 2021 --> Apr 2020; No longer pursuing development of serlopitantllllllllllmirikizumab (LY3074828) / Eli LillyA Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2) (clinicaltrials.gov) - Aug 21, 2020 - P3; N=1484; Completed; Sponsor: Eli Lilly and Company; Active, not recruiting --> Completed; Trial completion date: Dec 2020 --> May 2020llllllllllCosentyx (secukinumab) / NovartisMATURE: Study of Efficacy and Safety of Secukinumab 2 mL Auto-injector (300 mg) in Subjects With Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - Aug 18, 2020 - P3; N=122; Completed; Sponsor: Novartis Pharmaceuticals; Active, not recruiting --> CompletedllllllllllEnstilar (calcipotriene/betamethasone dipropionate) / LEO PharmaTo Study Generic Calcipotriene and Betamethasone Dipropionate Topical Foam, 0.005%/0.064%, in the Treatment of Psoriasis Vulgaris (Plaque Psoriasis). (clinicaltrials.gov) - Aug 19, 2020 - P3; N=494; Completed; Sponsor: Glenmark Pharmaceuticals Ltd. India; Recruiting --> Completed; Trial completion date: Oct 2019 --> Mar 2020; Trial primary completion date: Oct 2019 --> Mar 2020llllllllllBMS-986020 / BMS[VIRTUAL] Discovery of BMS-986202, a clinical Tyk2 JH2 inhibitor for the treatment of autoimmune and inflammatory diseases (ACS-Fall 2020) - Aug 20, 2020 - Abstract #MEDI 33; Pres time: Aug 17, 2020; 08:00 AM - 11:40 AM; Location: On Demand Oral; "We have previously reported that targeting the Tyk2 pseudokinase domain (JH2) is an innovative and effective approach to selectively mediating the Tyk2-dependent signaling cascade, leading to a compound currently in phase III clinical development for the treatment of psoriasis. We now report the discovery and pre-clinical studies of the clinical backup Tyk2 JH2 inhibitor BMS-986202."
